A Bioactive Fraction of Euphorbia antiquorum Stem Powder Ameliorates High‐Fat High‐Fructose Diet/Streptozotocin‐Induced Diabetes via GLUT‐4 Modulation
Chemistry & Biodiversity · 2026
DOI: 10.1002/cbdv.71521 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2026. Verfasst von Lunasmrita Saikia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutical Science, Assam Down Town University, Guwahati, Assam, India. Hauptthemen laut MEDLINE: Glucose Transporter Type 4, Euphorbia, Hypoglycemic Agents, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Euphorbia antiquorum L. (Euphorbiaceae), a traditionally used Asian medicinal plant, was systematically evaluated for its antidiabetic efficacy through a bioactivity‐guided approach integrating in vitro, in vivo, and in silico studies. Among the four solvent fractions of the ethanolic stem extract, the ethyl acetate fraction exhibited the highest antioxidant and glucose utilization activity. Column chromatography of the ethyl acetate fraction yielded several subfractions, among which Fraction 2 (CEA2) showed strong antioxidant activity and significantly enhanced glucose utilization and GLUT4 translocation (p < 0.01). In a 63‐day high‐fat high‐fructose diet and low‐dose streptozotocin‐induced diabetic rat model, CEA2 (200 and 400 mg/kg) markedly reduced fasting blood glucose, improved body weight, restored biochemical parameters, and decreased TNF‐α and IL‐6 levels, while also improving pancreatic and hepatic histopathology. Western blotting confirmed significant upregulation of plasma membrane GLUT4 (p < 0.01). LC‐MS profiling identified major compounds, including 3‐O‐trans‐p‐coumaroyltormentic acid and geranyl acetoacetate, which demonstrated strong binding to IRS‐1 and Akt‐PKB in docking and molecular dynamics analyses, key regulators of GLUT4 vesicle mobilization. This study provides one of the first comprehensive validations establishing CEA2 as a potent modulator of insulin signaling and GLUT4 mobilization, supporting E. antiquorum as a promising phytopharmaceutical candidate for type 2 diabetes management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmaceutical Science, Assam Down Town University, Guwahati, Assam, India.
- Programme of Biotechnology, Faculty of Science, Assam Down Town University, Guwahati, Assam, India.
- Center For Infectious Diseases, CSIR-North East Institute of Science and Technology, Jorhat, Assam, India.
- Faculty of Health and Life Sciences, Inti International University, Nilai, Negeri Sembilan, Malaysia.
- Department of Biotechnology, The Assam Royal Global University, Guwahati, Assam, India.
ORCID-Profile: Lunasmrita Saikia, Partha Pratim Dutta, Douglas Law
Zitieren
APA
Saikia, L., Dutta, P. P., Gogoi, D., Afzal, N. U., Manna, P., Law, D., Mandal, S., Gogoi, B., Gautam, M. K., & Sen, S. (2026). A Bioactive Fraction of Euphorbia antiquorum Stem Powder Ameliorates High‐Fat High‐Fructose Diet/Streptozotocin‐Induced Diabetes via GLUT‐4 Modulation. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.71521
Vancouver
Saikia L, Dutta PP, Gogoi D, Afzal NU, Manna P, Law D, et al. A Bioactive Fraction of Euphorbia antiquorum Stem Powder Ameliorates High‐Fat High‐Fructose Diet/Streptozotocin‐Induced Diabetes via GLUT‐4 Modulation. Chemistry & Biodiversity. 2026. doi:10.1002/cbdv.71521
BibTeX
@article{Saikia2026,
author = {Saikia, Lunasmrita and Dutta, Partha Pratim and Gogoi, Dhurbajyoti and Afzal, Nazim Unddin and Manna, Prasenjit and Law, Douglas and Mandal, Santa and Gogoi, Bhaskarjyoti and Gautam, Manish Kumar and Sen, Saikat},
title = {A Bioactive Fraction of Euphorbia antiquorum Stem Powder Ameliorates High‐Fat High‐Fructose Diet/Streptozotocin‐Induced Diabetes via GLUT‐4 Modulation},
journal = {Chemistry & Biodiversity},
year = {2026},
doi = {10.1002/cbdv.71521}
}
EUVIMED